Chiesi Global Rare Diseases receives Swissmedic approval for FILSUVEZ® topical gel for the treatment of epidermolysis bullosa
11 Agosto 2025
Chiesi Group and Serna Bio announce strategic collaboration to discover and develop RNA-targeted small molecules for respiratory diseases
24 Luglio 2025
Elgan Pharma and Chiesi Group Announce First Participating Infants Dosed in Phase 3 Study of ELGN-2112 for Treatment of Intestinal Malabsorption in Preterm Infants
Chiesi Group delivers on transformational strategy with FY2024 double-digit growth (13% at CER), strong investment in innovation and continued focus on sustainability
16 Aprile 2025
Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth
26 Marzo 2025
Chiesi Group appoints three new independent Non-Executive Directors to its Board, supporting company evolution and growth
29 Gennaio 2025
Great Place To Work and Fortune Name Chiesi Group No. 23 in 2024 World’s Best Workplaces™ List
14 Novembre 2024
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
30 Settembre 2024
Chiesi Group Unveils Innovations in Respiratory Care, Patient Insights into Decentralization of a Clinical Trial and Developments in Carbon Minimal Inhaler Project at ERS Congress 2024
